HEG Advanced Materials, ESDS, Maruti Suzuki, Zydus Wellness among buzzing stocks as NIFTY, SENSEX down 0.6%

Benchmark equity indices NIFTY50 and SENSEX declined on Monday, September 7, amid elevated crude oil prices, concerns over a possible US interest rate hike and escalation in US-Iran hostilities.

The NIFTY50 index fell 0.59% to 23,756, while SENSEX descended 489 points, or 0.64%, to 76,022.

Infosys, Tech Mahindra, SBI Life, HCLTech, Trent, Tata Steel, Wipro, Jio Financial Services, TCS, UltraTech Cement, HDFC Life, JSW Steel and Asian Paints were among the major laggards from the NIFTY pack.

Apollo Hospitals, Eicher Motors, Marti Suzuki, Coal India, Max Healthcare, and Power Grid were among top gainers.

HEG has reorganised into two separate entities. The scheme provides for the demerger of the company's graphite electrodes business into a separate firm (HEG Graphite Limited). HEG Graphite will be listed on NSE and BSE in 45 days, likely in the second half of October.

"The reorganisation gives each business an independent listing, a focused management and the flexibility to pursue its own growth path," the company said in an exchange filing.

The company's shares were listed at ₹757 per share, a premium of 76.46% over the issue price, on NSE on September 4.

The initial public offering was a fresh issuance of 1.68 crore shares valued at ₹720 crore, with no offer for sale (OFS) component.

The scrip had hit its 52-week high of ₹611.84 per share on July 20, 2026, while its year's low of ₹367.55 apiece was recorded on March 2, 2026.

The scrip has surged 3.74% in the past week and 3.07% in a month. Year-to-date, it rose 18.52%.

"For the past few months, the Company has been making continuous efforts to mitigate the cost impact to the extent possible through cost reduction measures. However, with inflationary burdens at elevated levels and the adverse cost environment enduring, the Company is constrained to pass on a portion of the increased costs to the market while continuing to ensure that the impact on customers is kept to the minimum extent possible," it said.

In a regulatory filing, the firm noted that Minipress XL (containing prazosin) is primarily indicated in India for managing hypertension (high blood pressure) and treating the urinary symptoms of benign prostatic hyperplasia (BPH).

According to IQVIA MAT July 2026 data, Minipress XL posted revenue of ₹228.6 crore and has been growing at a CAGR of 6.3% for the past four years.

Following the announcement, the stock was up 0.38% to ₹1,653.